col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

160 Results       Page 1

Elsevier: Clinical Immunology
  original article Date Title Authors   All Authors
1 [GO] 2023―Nov―22 Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk Marc Emmenegger, Vishalini Emmenegger, Srikanth Mairpady Shambat, Thomas C. Scheier, Alejandro Gomez-Mejia, Chun-Chi Chang, et al. (+6)
2 [GO] 2023―Nov―10 Enoxaparin improves COVID-19 by reducing Neutrophils Extracellular Traps (NETs) production Emily S. Córneo, Flavio Protasio Veras, Giovanni F. Gomes, Ayda H. Schneider, Bruna Manuella, Cicero J.L.R. Almeida, et al. (+13)
3 [GO] 2023―Oct―16 Multi-omic profiling reveals early immunological indicators for identifying COVID-19 Progressors Katherine A. Drake, Dimitri Talantov, Gary J. Tong, Jack T. Lin, Simon Verheijden, Samuel Katz, et al. (+22)
4 [GO] 2023―Oct―11 T regulatory lymphocytes specific for SARS-CoV-2 display increased functional plasticity Laura Esparcia-Pinedo, Ángel Lancho-Sánchez, Ilya Tsukalov, María I. Pacheco, Pedro Martínez-Fleta, Belén Pérez-Miés, et al. (+4)
5 [GO] 2023―Sep―03 Similarities and differences between myocarditis following COVID-19 mRNA vaccine and multiple inflammatory syndrome with cardiac involvement in children Donato Amodio, Giuseppe Rubens Pascucci, Nicola Cotugno, Chiara Rossetti, Emma Concetta Manno, Chiara Pighi, et al. (+13)
6 [GO] 2023―Aug―14 Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations Chuang-Wei Wang, Ming-Ying Wu, Chun-Bing Chen, Wei-Chen Lin, Jennifer Wu, Chun-Wei Lu, et al. (+11)
7 [GO] 2023―Jul―26 Cytolytic CD8+ T cell response to SARS-CoV-2 and non-SARS-CoV-2-related viruses is associated with severe manifestation of COVID-19 Kristina Allers, Verena Moos, Jörg Hofmann, Mario Witkowski, Hildrun Haibel, Stefan Angermair, Thomas Schneider
8 [GO] 2023―Jul―22 Behçet's patients' response to COVID-19 vaccination Bindi Gokani, Sarah Sacoor, Georgia R. Leisegang, William Ogunkolade, Azimoon Bibi, Sofia Grigoriadou, et al. (+4)
9 [GO] 2023―Jul―13 SARS-COV-2 specific t-cells in patients with thyroid disorders related to COVID-19 are enriched in the thyroid and acquire a tissue-resident memory phenotype Silvestri Ylenia, Clemente Francesca, Moschetti Giorgia, Maioli Sara, Carelli Elena, Espadas de Arias Alejandro, et al. (+14)
10 [GO] 2023―Jul―05 NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19 Huiqing Lin, Jiejie Liu, Ning Li, Birong Zhang, Van Dien Nguyen, Peipei Yao, et al. (+6)
11 [GO] 2023―May―30 Increase in the number of new cases of ANCA-associated vasculitis in the COVID-19 vaccine era Tomohito Sato, Masataka Umeda, Shuntaro Sato, Toru Michitsuji, Toshimasa Shimizu, Tomohiro Koga, et al. (+2)
12 [GO] 2023―May―23 Association of SARS-COV-2 viral RNAemia, IL- 6 gene polymorphism, serum IL-6 and peripheral blood lymphocytes and monocytes with disease severity in COVID-19 patients Shirin Tarafder, Nur Mohammad Khan
13 [GO] 2023―May―23 Retrospective Study on Vaccine Responses and Natural Course of COVID-19 Infections in Primary Immunodeficiency Tracy Hwangpo, Harry Schroeder
14 [GO] 2023―May―23 COVID-19-Related Encephalitis in a Child with PIK3CD Defect David Potts, Melis Yilmaz, Priya Patel, Minh Nguyen, Joseph Dasso, Boglarka Ujhazi, et al. (+4)
15 [GO] 2023―May―23 Anti-interferon-alpha autoantibodies in patients with inborn errors of Immunity and rheumatic diseases before and during the COVID-19 pandemic Joseph Dasso, Boglarka Ujhazi, Peter Illes, Sumai Gordon, Serena Shaffren, Eugenia Alas, et al. (+3)
16 [GO] 2023―May―23 Characteristics and Clinical Implications of Anti-IFN-α cytokine antibodies in partial Recombinase Activating Gene Deficiency patients before and during the COVID-19 Pandemic Sumai Gordon, Melis Yilmaz, Joseph Dasso, Caterina Cancrini, Karlla Brigatti, Kevin Strauss, et al. (+4)
17 [GO] 2023―May―23 A comprehensive knowledgebase of known and predicted human genetic variants associated with COVID-19 susceptibility and severity Meltem Ece Kars, David Stein, Cigdem Sevim Bayrak, Peter Stenson, David Cooper, Yuval Itan
18 [GO] 2023―May―23 Fatal COVID-19 in an infant prompted an early diagnosis of ZNFX1 deficiency in a sibling Raed Alzyoud, Motasem Alsuweiti
19 [GO] 2023―May―23 Mild COVID-19 clinical course among paediatric patients with primary immunodeficiency Marina Sham, Myra Pereira, Linda Vong, Laura Abrego Fuentes, Abdulrahman Al Ghamdi, Ori Scott, et al. (+3)
20 [GO] 2023―May―23 Mild COVID-19 outcomes in adults with inborn errors of immunity: a single-center experience Laura Abrego Fuentes, Marina Sham, Myra Pereira, Linda Vong, Ori Scott, Abdulrahman Al Ghamdi, Chaim Roifman
21 [GO] 2023―May―23 A Case of a Relapsing Remitting Macrophage Activating Syndrome After Covid-19 Vaccine In a Teenager with UNC13D Heterozygous Variant of Uncertain Significance Jessica Simpson, Hanadys Ale, Kristina Wiers-Shamir
22 [GO] 2023―May―23 Surveillance of anti-SARS-CoV-2 antibodies in plasma pools and in immunoglobulin medicinal products manufactured since 2020 has shown high neutralizing activity against SARS-CoV-2 and current variants Carolina Romero, José María Diez, Rodrigo Gajardo
23 [GO] 2023―May―23 Association Between Severe SARS-CoV-2 Infection and De Novo HLA Donor Specific Antibody Production in Lung Transplant Recipients: Single-center study Sadia Shah, Zeying Du, Si Pham, Mohamed Elrefaei
24 [GO] 2023―May―23 Immunoglobulin replacement products in current clinical use in the United States have poor neutralizing activity against SARS-CoV-2 Omicron strains Alexa Doss, Chieh-Yu Liang, Jennifer Monroy, James Wedner, Christopher Rigell, Hannah Davis-Adams, et al. (+4)
25 [GO] 2023―May―23 Characterization of Adaptive Immune Responses to SARS-CoV-2 Updated Bivalent Booster Brianna Wachter, Kalpana Manthiram, Qin Xu, Lihong Shi, Pamela Schwartzberg, Peter Burbelo, et al. (+4)
26 [GO] 2023―May―23 Patients with hereditary angioedema and patients with SARS-CoV-2-associated pneumonia - what can be similar? Irina Guryanova, Aliaksandr Liubushkin, Viktoria Kazak, Yulia Zharankova, Inessa Doronina, Alexandr Migas, Mikhail Belevtsev
27 [GO] 2023―May―05 Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patients Andrew D. Hoffmann, Sam E. Weinberg, Suchitra Swaminathan, Shuvam Chaudhuri, Hannah Faisal Mubarak, Matthew J. Schipma, et al. (+17)
28 [GO] 2023―May―03 Corrigendum to “Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine” [Clinical Immunology 237 (2022) 108963] Matthew K. Wong, Jun T. Liu, Patrick Budylowksi, Feng Yun Yue, Zhijie Li, James M. Rini, et al. (+4)
29 [GO] 2023―Apr―28 Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19 June-Young Koh, Jae-Hoon Ko, So Yun Lim, Seongman Bae, Kyungmin Huh, Sun Young Cho, et al. (+6)
30 [GO] 2023―Apr―24 Pre-existing humoral immunity and CD4+ T cell response correlate with cross-reactivity against SARS-CoV-2 Omicron subvariants after heterologous prime-boost vaccination Ching-Fen Shen, Yi-Chen Fu, Tzong-Shiann Ho, Po-Lin Chen, Nan-Yao Lee, Bo-Yang Tsai, et al. (+5)
31 [GO] 2023―Feb―20 Adaptive immune dysfunction in patients with COVID-19 and impaired kidney function during the omicron surge Jiayi Yan, Jieying Wang, Li Ding, Shang Liu, Yaping Zhan, Jiayue Lu, et al. (+9)
32 [GO] 2023―Feb―16 Chronic stimulation with SARS-CoV-2 spike protein does not trigger autoimmunity Marc Scherlinger, Jean Sibilia, George C. Tsokos, Jacques-Eric Gottenberg
33 [GO] 2023―Jan―28 Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination Andreas Törnell, Hanna Grauers Wiktorin, Johan Ringlander, Mohammad Arabpour, Staffan Nilsson, Magnus Lindh, et al. (+3)
34 [GO] 2023―Jan―21 Down-regulation of KLF2 in lung fibroblasts is linked with COVID-19 immunofibrosis and restored by combined inhibition of NETs, JAK-1/2 and IL-6 signaling Akrivi Chrysanthopoulou, Christina Antoniadou, Anastasia-Maria Natsi, Efstratios Gavriilidis, Vasileios Papadopoulos, Evangelia Xingi, et al. (+7)
35 [GO] 2022―Dec―29 Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices Panagiotis G. Asteris, Styliani Kokoris, Eleni Gavriilaki, Markos Z. Tsoukalas, Panagiotis Houpas, Maria Paneta, et al. (+15)
36 [GO] 2022―Dec―17 Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19 Weng Hua Khoo, Katherine Jackson, Chansavath Phetsouphanh, John J. Zaunders, José Alquicira-Hernandez, Seyhan Yazar, et al. (+32)
37 [GO] 2022―Nov―08 Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities Murad Alahdal, Eyad Elkord
38 [GO] 2022―Oct―08 Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose Emily Rose, Daniel Magliulo, Vasileios C. Kyttaris
39 [GO] 2022―Sep―30 Immunological characteristics of severe acute hepatitis of unknown origin in a child post SARS-CoV-2 infection Atsushi Morita, Kazuo Imagawa, Kei Asayama, Tsubasa Terakado, Shoko Takahashi, Katsuyuki Yaita, et al. (+3)
40 [GO] 2022―Aug―30 Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors Bi-Nan Lu, Ka-Li Zhu, Xiao-Ming Cui, Lin Yao, Xue-Jun Wang, Guo-Lin Wang, et al. (+3)
41 [GO] 2022―Aug―30 SARS-CoV-2-specific T cell responses in patients with multisystem inflammatory syndrome in children Ki Pui Lam, Marcos Chiñas, Amélie M. Julé, Maria Taylor, Marina Ohashi, Mehdi Benamar, et al. (+9)
42 [GO] 2022―Aug―13 COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review Emily Drzymalla, Ridgely Fisk Green, Martha Knuth, Muin J. Khoury, W. David Dotson, Adi Gundlapalli
43 [GO] 2022―Aug―06 Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19 Yuan-Yuan Yong, Li Zhang, Yu-Jiao Hu, Jian-Ming Wu, Lu Yan, Yi-Ru Pan, et al. (+9)
44 [GO] 2022―Aug―06 Decrease in CD8+CD45+CCR7+CD62L+ T cells in individuals vaccinated with Sinovac-CoronaVac following COVID-19 infection Dâmaris C.S.C. Fonseca, Mirtes C.B. Rocha, Lucca A. Pereira, Leticia P. Botega, Susanne C.P.F. Cutrim, Fabiano V. Silva, et al. (+7)
45 [GO] 2022―Aug―06 Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: An Italian experience Maria Infantino, Lorenza Morena, Massimo Antonio Di Pietro, Benedetta Romanin, Barbara Cimolato, Beatrice Anna Luisa Rocca, et al. (+13)
46 [GO] 2022―Jun―25 High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19 Mirko Scordio, Federica Frasca, Letizia Santinelli, Leonardo Sorrentino, Alessandra Pierangeli, Ombretta Turriziani, et al. (+5)
47 [GO] 2022―May―02 SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination Edgardo Guzman Rivera, Asha Patnaik, Joann Salvemini, Sanjeev Jain, Katherine Lee, Daniel Lozeau, Qingping Yao
48 [GO] 2022―Apr―27 Myeloid-derived suppressor cells in COVID-19: A review Yuliya V. Perfilyeva, Yekaterina O. Ostapchuk, Raikhan Tleulieva, Aykin Kali, Nurshat Abdolla, Vladimir K. Krasnoshtanov, et al. (+2)
49 [GO] 2022―Apr―26 Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update Wen Zhang, Chenman Qin, Yunyun Fei, Min Shen, Yangzhong Zhou, Yan Zhang, et al. (+2)
50 [GO] 2022―Apr―18 Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure Efstratios Gavriilidis, Christina Antoniadou, Akrivi Chrysanthopoulou, Maria Ntinopoulou, Andreas Smyrlis, Iliana Fotiadou, et al. (+13)
51 [GO] 2022―Apr―07 Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients Masaru Takeshita, Naoshi Nishina, Saya Moriyama, Yoshimasa Takahashi, Makoto Ishii, Hideyuki Saya, et al. (+5)
52 [GO] 2022―Apr―05 Protective HLA alleles against severe COVID-19: HLA-A*68 as an ancestral protection allele in Tapachula-Chiapas, Mexico Susana Hernández-Doño, Roberto Alejandro Sánchez-González, Ma Guadalupe Trujillo-Vizuet, Fabiola Yeseline Zamudio-Castellanos, Rafael García-Silva, Pedro Bulos-Rodríguez, et al. (+9)
53 [GO] 2022―Mar―29 Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19 Naoki Kaneko, Julie Boucau, Hsiao-Hsuan Kuo, Cory Perugino, Vinay S. Mahajan, Jocelyn R. Farmer, et al. (+13)
54 [GO] 2022―Mar―23 Pandemic chilblains: Are they SARS-CoV-2-related or not? Axel De Greef, Pierre G. Coulie, Marie Baeck
55 [GO] 2022―Mar―17 Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants Divya Gupta, Farhan Ahmed, Dixit Tandel, Haripriya Parthasarathy, Dhiviya Vedagiri, Vishal Sah, et al. (+9)
56 [GO] 2022―Mar―14 Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response Yves Renaudineau, Florence Abravanel, Jacques Izopet, Chloé Bost, Emmanuel Treiner, Nicolas Congy, Antoine Blancher
57 [GO] 2022―Mar―05 Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine Matthew K. Wong, Jun T. Liu, Patrick Budylowksi, Feng Yun Yue, Zhijie Li, James M. Rini, et al. (+4)
58 [GO] 2022―Feb―25 Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis Hristos Karakizlis, Christian Nahrgang, Kevin Strecker, Jiangping Chen, Mostafa Aly, Heiko Slanina, et al. (+12)
59 [GO] 2022―Feb―24 A global survey in the developmental landscape of possible vaccination strategies for COVID-19 Amin Gasmi, Shvetha Srinath, Maryam Dadar, Lyudmila Pivina, Alain Menzel, Asma Gasmi Benahmed, et al. (+2)
60 [GO] 2022―Feb―24 Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response Paul S. Kim, Derek E. Dimcheff, Andrew Siler, Richard J. Schildhouse, Stephen W. Chensue
61 [GO] 2022―Feb―09 The FCGR2Ars1801274 polymorphism was associated with the risk of death among COVID-19 patients Rocío López-Martínez, Guillermo M. Albaiceta, Laura Amado-Rodríguez, Elías Cuesta-Llavona, Juan Gómez, Marta García-Clemente, et al. (+3)
62 [GO] 2022―Jan―25 Protracted or recurrent COVID-19 associated cytokine storm in a patient with chronic lymphocytic leukemia receiving rituximab-based chemotherapy Murat Bektaş, Gökhan Özdemir
63 [GO] 2022―Jan―19 Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study Mahmoud M. Alseoudy, Mohamed Elgamal, Dalia A. Abdelghany, Asmaa M. Borg, Ahmed El-Mesery, Dina Elzeiny, Maha O. Hammad
64 [GO] 2021―Dec―29 Evaluation of serological anti-SARS-CoV-2 chemiluminescent immunoassays correlated to live virus neutralization test, for the detection of anti-RBD antibodies as a relevant alternative in COVID-19 large-scale neutralizing activity monitoring Antonio Cristiano, Massimo Pieri, Serena Sarubbi, Martina Pelagalli, Graziella Calugi, Flaminia Tomassetti, et al. (+2)
65 [GO] 2021―Dec―18 Association of KIR gene polymorphisms with COVID-19 disease Ali Hajeer, Dunia Jawdat, Salam Massadeh, Nora Aljawini, Malak S. Abedalthagafi, Yaseen M. Arabi, Manal Alaamery
66 [GO] 2021―Nov―27 Immunogenicity of SARS-CoV2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters Daniel Magliulo, Stefanie D. Wade, Vasileios C. Kyttaris
67 [GO] 2021―Nov―16 Role of NRF2 and Sirtuin activators in COVID-19 Hasnat Khan, Shivangi Patel, Anuradha Majumdar
68 [GO] 2021―Nov―09 Adult-onset Still's disease following mRNA COVID-19 vaccination Amir Sharabi, Shachaf Shiber, Yair Molad
69 [GO] 2021―Oct―05 Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors Thomas W. Barnes, Johannes Schulte-Pelkum, Laura Steller, Daniel Filchtinski, Robin Jenness, Michelle R. Williams, et al. (+8)
70 [GO] 2021―Sep―30 Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19 Jiezhong Chen, Luis Vitetta
71 [GO] 2021―Sep―24 A hitchhiker's guide through the COVID-19 galaxy Susanna Felsenstein, Andreas Otto Reiff
72 [GO] 2021―Sep―24 Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey Shirley Shapiro Ben David, Na’ama Shamir-Stein, Sharon Baruch Gez, Uri Lerner, Daniella Rahamim-Cohen, Anat Ekka Zohar
73 [GO] 2021―Sep―22 A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults Junghee J. Shin, Sangchoon Jeon, Serhan Unlu, Jennefer Par-Young, Min Sun Shin, John K. Kuster, et al. (+6)
74 [GO] 2021―Sep―11 Inflammation/coagulopathy/fibrinolysis: Dynamic indicators of COVID-19 progression in patients with moderate COVID-19 in Wenzhou, China Shengwei Jin, Hui An, Tong Zhou, Ting Li, Chengshui Chen, Binyu Ying, et al. (+3)
75 [GO] 2021―Sep―08 Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue Waleed H. Mahallawi, Talal M. Aljeraisi
76 [GO] 2021―Aug―31 Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year Giuseppe A. Ramirez, Lorenza M. Argolini, Chiara Bellocchi, Luca Moroni, Emanuel Della-Torre, Nicola Farina, et al. (+5)
77 [GO] 2021―Aug―27 Immunomodulation and immunotherapeutics of COVID-19 Sourbh Suren Garg, Atulika Sharma, Jeena Gupta
78 [GO] 2021―Aug―21 Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients Kavita Mathi, Yael Rosenberg-Hasson, Holden Maecker, Dennis J. Carlo, Ronald B. Moss
79 [GO] 2021―Aug―13 Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility Yashini Govender, Sharon Shalekoff, Osman Ebrahim, Ziyaad Waja, Richard E. Chaisson, Neil Martinson, Caroline T. Tiemessen
80 [GO] 2021―Aug―12 COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era A. Deya-Martinez, A. García-García, E.A. Gonzalez-Navarro, L. Yiyi, A. Vlagea, I. Jordan, et al. (+8)
81 [GO] 2021―Aug―04 Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine Miguel García-Grimshaw, Anaclara Michel-Chávez, Juan Mauricio Vera-Zertuche, Javier Andrés Galnares-Olalde, Laura E. Hernández-Vanegas, Melissa Figueroa-Cucurachi, et al. (+6)
82 [GO] 2021―Aug―02 BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review Michael Stack, Keith Sacco, Riccardo Castagnoli, Alicia A. Livinski, Luigi D. Notarangelo, Michail S. Lionakis
83 [GO] 2021―Jul―31 Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection Puya Dehgani-Mobaraki, Asiya Kamber Zaidi, Nidhi Yadav, Alessandro Floridi, Emanuela Floridi
84 [GO] 2021―Jul―23 Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach Ananya Das, Sraddhya Roy, Snehasikta Swarnakar, Nabanita Chatterjee
85 [GO] 2021―Jul―21 COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City Kaoru Harada, Hsi-en Ho, Charlotte Cunningham-Rundles
86 [GO] 2021―Jul―10 Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19 Simin Jamaly, Maria G. Tsokos, Rhea Bhargava, Olga R. Brook, Jonathan L. Hecht, Reza Abdi, et al. (+3)
87 [GO] 2021―Jun―29 Detection of immunoglobulin response to COVID-19 vaccination using a novel rapid fingerstick assay Beth L. Cobb, Amr H. Sawalha
88 [GO] 2021―Jun―29 Severe COVID-19 pneumonia in Good syndrome with a favorable outcome Maria Lourdes Cos Esquius, Inmaculada López Montesinos, Ramón Gimeno Martinez, Jorge Eguía Núñez, M. Araceli Caballero-Rabasco, Blanca Sánchez González, et al. (+2)
89 [GO] 2021―Jun―18 Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study Miguel García-Grimshaw, Santa Elizabeth Ceballos-Liceaga, Laura E. Hernández-Vanegas, Isaac Núñez, Noé Hernández-Valdivia, Daniel Amado Carrillo-García, et al. (+17)
90 [GO] 2021―Jun―09 Seroprevalence and SARS-CoV-2 cross-reactivity of endemic coronavirus OC43 and 229E antibodies in Finnish children and adults Kirsi Tamminen, Marjo Salminen, Vesna Blazevic
91 [GO] 2021―Jun―02 Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus Panagiotis A. Ntouros, Nikolaos I. Vlachogiannis, Maria Pappa, Adrianos Nezos, Clio P. Mavragani, Maria G. Tektonidou, et al. (+2)
92 [GO] 2021―Apr―28 IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report Raffaele Badolato, Marco Cattalini, Rosaria Scaduto, Sara Roversi, Jessica Galli, Rosalba Monica Ferraro, et al. (+4)
93 [GO] 2021―Apr―28 Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation Viktorija Erdeljic Turk
94 [GO] 2021―Apr―22 SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts Christopher Thor Freda, Wei Yin, Berhane Ghebrehiwet, David A. Rubenstein
95 [GO] 2021―Apr―19 A novel application of delayed-type hipersensitivity reaction to measure cellular immune response in SARS-CoV-2 exposed individuals Yvelise Barrios, Andres Franco, Inmaculada Sanchez-Machin, Paloma Poza-Guedes, Ruperto Gonzalez-Perez, Victor Matheu
96 [GO] 2021―Apr―15 Genetic justification of severe COVID-19 using a rigorous algorithm Eleni Gavriilaki, Panagiotis G. Asteris, Tasoula Touloumenidou, Evaggelia-Evdoxia Koravou, Maria Koutra, Penelope Georgia Papayanni, et al. (+26)
97 [GO] 2021―Apr―09 The microbiota-mediated dietary and nutritional interventions for COVID-19 Amin Gasmi, Torsak Tippairote, Pavan Kumar Mujawdiya, Massimiliano Peana, Alain Menzel, Maryam Dadar, et al. (+2)
98 [GO] 2021―Apr―07 Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products Ariel Kenig, Yuval Ishay, Fadi Kharouf, Limor Rubin
99 [GO] 2021―Apr―03 Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon Karolina Akinosoglou, Ilektra Tzivaki, Markos Marangos
100 [GO] 2021―Apr―02 Serum levels of SARS-CoV-2 nucleocapsid antigen associate with inflammatory status and disease severity in COVID-19 patients Francesco Perna, Sara Bruzzaniti, Erica Piemonte, Valeria Maddaloni, Lidia Atripaldi, Silvia Sale, et al. (+7)
101 [GO] 2021―Mar―24 Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19 Abhigyan Satyam, Maria G. Tsokos, Olga R. Brook, Jonathan L. Hecht, Vaishali R. Moulton, George C. Tsokos
102 [GO] 2021―Mar―07 Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study Meruyert Dauletova, Hafsan Hafsan, Negah Mahhengam, Angelina Olegovna Zekiy, Majid Ahmadi, Homayoon Siahmansouri
103 [GO] 2021―Feb―25 The role of A-to-I RNA editing in infections by RNA viruses: Possible implications for SARS-CoV-2 infection Nikolaos I. Vlachogiannis, Kleio-Maria Verrou, Konstantinos Stellos, Petros P. Sfikakis, Dimitrios Paraskevis
104 [GO] 2021―Feb―21 Coronavirus-induced autoimmunity Valéry Salle
105 [GO] 2021―Feb―16 Temporal viral loads in respiratory and gastrointestinal tract and serum antibody responses during SARS-CoV-2 infection in an Italian pediatric cohort Francesca Caccuri, Antonella Bugatti, Antonella Meini, Carlo Bonfanti, Mario Motta, Lucia Savarè, et al. (+5)
106 [GO] 2021―Feb―05 Common hematological values predict unfavorable outcomes in hospitalized COVID-19 patients Isaac Núñez, Ángel A. Priego-Ranero, H. Benjamín García-González, Brenda Jiménez-Franco, Rebeca Bonilla-Hernández, Guillermo Domínguez-Cherit, et al. (+4)
107 [GO] 2021―Jan―12 Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” Rossella Talotta
108 [GO] 2021―Jan―09 SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency Nicolai S.C. van Oers, Natasha W. Hanners, Paul Sue, Victor Aquino, Quan-Zhen Li, John W. Schoggins, Christian A. Wysocki
109 [GO] 2020―Dec―16 Interrelations between COVID-19 and other disorders Amin Gasmi, Massimiliano Peana, Lyudmila Pivina, Shvetha Srinath, Asma Gasmi Benahmed, Yuliya Semenova, et al. (+3)
110 [GO] 2020―Dec―16 Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned Varvara A. Ryabkova, Leonid P. Churilov, Yehuda Shoenfeld
111 [GO] 2020―Dec―08 Fatal SARS-CoV-2 infection in a male patient with Good's syndrome Maria Rosa Pozzi, Manuela Baronio, Maria Bianchi Janetti, Luisa Gazzurelli, Daniele Moratto, Marco Chiarini, et al. (+2)
112 [GO] 2020―Dec―07 Kawasaki or Kawasaki-like disease? A debate on COVID-19 infection in children Mohammad-Salar Hosseini
113 [GO] 2020―Nov―28 Peripheral immunological features of COVID-19 patients in Taizhou, China: A retrospective study Xiao-Hong Jin, Hui-Li Zhou, Ling-Ling Chen, Guan-Fu Wang, Qiu-Yue Han, Jian-Gang Zhang, et al. (+5)
114 [GO] 2020―Nov―17 COVID-19: A review of therapeutic strategies and vaccine candidates Vladislav Izda, Matlock A. Jeffries, Amr H. Sawalha
115 [GO] 2020―Nov―13 Major reduction of NKT cells in patients with severe COVID-19 pneumonia Maria Antonella Zingaropoli, Valentina Perri, Patrizia Pasculli, Francesco Cogliati Dezza, Parni Nijhawan, Giulia Savelloni, et al. (+6)
116 [GO] 2020―Nov―12 Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort Hèctor Corominas, Ivan Castellví, Virginia Pomar, Rosa Antonijoan, Isabel Mur, Laia Matas, et al. (+11)
117 [GO] 2020―Oct―27 Commentary on “Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy” by D.C. Mastellos et al. Isabel Kinney Ferreira de Miranda Santos, Cristina Ribeiro de Barros Cardoso
118 [GO] 2020―Oct―25 Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19 Dimitrios C. Mastellos, John D. Lambris
119 [GO] 2020―Oct―23 Laboratory biomarkers associated with COVID-19 severity and management S. Keddie, O. Ziff, M.K.L. Chou, R.L. Taylor, A. Heslegrave, E. Garr, et al. (+9)
120 [GO] 2020―Oct―23 An enlightening role for cytokine storm in coronavirus infection Zhongyi Zhao, Yinhao Wei, Chuanmin Tao
121 [GO] 2020―Oct―14 Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients Chun Gao, Li Zhu, Cheng Cheng Jin, Yi Xin Tong, Ai Tang Xiao, Sheng Zhang
122 [GO] 2020―Sep―19 Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy Dimitrios C. Mastellos, Bruno G.P. Pires da Silva, Benedito A.L. Fonseca, Natasha P. Fonseca, Maria Auxiliadora-Martins, Sara Mastaglio, et al. (+17)
123 [GO] 2020―Sep―10 On the genetics and immunopathogenesis of COVID-19 Chaim Oscar Jacob
124 [GO] 2020―Sep―06 SARS-CoV-2 infections in children and young people Susanna Felsenstein, Christian M. Hedrich
125 [GO] 2020―Aug―29 Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients María Caridad Montalvo Villalba, Odalys Valdés Ramirez, Mayra Muné Jiménez, Amely Arencibia Garcia, Javier Martinez Alfonso, Guelsy González Baez, et al. (+6)
126 [GO] 2020―Aug―15 Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients Ignacio Iturrieta-Zuazo, Claudia Geraldine Rita, Ana García-Soidán, Ana de Malet Pintos-Fonseca, Nieves Alonso Alarcón, Roberto Pariente Rodríguez, et al. (+4)
127 [GO] 2020―Aug―06 Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19 Jeffrey Laurence, J. Justin Mulvey, Madhav Seshadri, Alexandra Racanelli, Joanna Harp, Edward J. Schenck, et al. (+3)
128 [GO] 2020―Jul―31 Critical COVID-19 disease, homeostasis, and the “surprise” of effective glucocorticoid therapy G.P. Chrousos, G.U. Meduri
129 [GO] 2020―Jul―23 Micronutrients as immunomodulatory tools for COVID-19 management Amin Gasmi, Torsak Tippairote, Pavan Kumar Mujawdiya, Massimiliano Peana, Alain Menzel, Maryam Dadar, et al. (+2)
130 [GO] 2020―Jul―22 Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine Homam Ibrahim, Andras Perl, Deane Smith, Tyler Lewis, Zachary Kon, Ronald Goldenberg, et al. (+3)
131 [GO] 2020―Jul―13 mTORC inhibitor Sirolimus deprograms monocytes in “cytokine storm” in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome Claudio Karsulovic, Mercedes Lopez, Fabian Tempio, Julia Guerrero, Annelise Goecke
132 [GO] 2020―Jul―12 Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation? James R. McIlroy, Benjamin H. Mullish, Simon D. Goldenberg, Gianluca Ianiro, Julian R. Marchesi
133 [GO] 2020―Jul―11 Long-term infection of SARS-CoV-2 changed the body's immune status Lan Lin, Shanshan Luo, Renjie Qin, Mengling Yang, Xiaobei Wang, Qianqian Yang, et al. (+8)
134 [GO] 2020―Jun―27 Imatinib for COVID-19: A case report Alejandro Morales-Ortega, David Bernal-Bello, Cristina Llarena-Barroso, Begoña Frutos-Pérez, Miguel Ángel Duarte-Millán, Vanessa García de Viedma-García, et al. (+5)
135 [GO] 2020―Jun―23 Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment Swamy Yeleswaram, Paul Smith, Timothy Burn, Maryanne Covington, Ashish Juvekar, Yanlong Li, et al. (+2)
136 [GO] 2020―Jun―20 COVID-19 pneumonia: CD8+ T and NK cells are decreased in number but compensatory increased in cytotoxic potential Yujie Jiang, Xin Wei, Jingjing Guan, Shuang Qin, Zhongyong Wang, Hong Lu, et al. (+5)
137 [GO] 2020―Jun―13 Development of child immunity in the context of COVID-19 pandemic Małgorzata Kloc, Rafik M. Ghobrial, Ernest Kuchar, Sławomir Lewicki, Jacek Z. Kubiak
138 [GO] 2020―Jun―12 Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy Ciceri Fabio, Castagna Antonella, Rovere-Querini Patrizia, De Cobelli Francesco, Ruggeri Annalisa, Galli Laura, et al. (+27)
139 [GO] 2020―Jun―09 Antibody-dependent enhancement and COVID-19: Moving toward acquittal Eric J. Yager
140 [GO] 2020―Jun―08 A plea for the pathogenic role of immune complexes in severe Covid-19 Dominique A. Vuitton, Lucine Vuitton, Estelle Seillès, Pierre Galanaud
141 [GO] 2020―May―31 Treating COVID-19 with colchicine in community healthcare setting Emanuel Della-Torre, Fabrizio Della-Torre, Marija Kusanovic PCP, Raffaella Scotti, Giuseppe Alvise-Ramirez, Lorenzo Dagna, Moreno Tresoldi
142 [GO] 2020―May―29 Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients J.M. Urra, C.M. Cabrera, L. Porras, I. Ródenas
143 [GO] 2020―May―29 Type 3 hypersensitivity in COVID-19 vasculitis Luca Roncati, Giulia Ligabue, Luca Fabbiani, Claudia Malagoli, Graziana Gallo, Beatrice Lusenti, et al. (+3)
144 [GO] 2020―May―28 Racial disparity in Covid-19 mortality rates - A plausible explanation Yuval Tal, Avner Adini, Alal Eran, Irit Adini
145 [GO] 2020―May―24 Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Aristo Vojdani, Datis Kharrazianb
146 [GO] 2020―May―21 Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? Loukman Omarjee, Olivier Meilhac, Frédérique Perrot, Anne Janin, Guillaume Mahe
147 [GO] 2020―May―15 Supplements for COVID-19: A modifiable environmental risk Trevor K. Young, John G. Zampella
148 [GO] 2020―May―13 Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19 Loukman Omarjee, Anne Janin, Frédérique Perrot, Bruno Laviolle, Olivier Meilhac, Guillaume Mahe
149 [GO] 2020―May―11 Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Alan A. Nguyen, Saddiq B. Habiballah, Craig D. Platt, Raif S. Geha, Janet S. Chou, Douglas R. McDonald
150 [GO] 2020―Apr―29 The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 Sara Mastaglio, Annalisa Ruggeri, Antonio M. Risitano, Piera Angelillo, Despina Yancopoulou, Dimitrios C. Mastellos, et al. (+6)
151 [GO] 2020―Apr―27 COVID-19: Immunology and treatment options Susanna Felsenstein, Jenny A. Herbert, Paul S. McNamara, Christian M. Hedrich
152 [GO] 2020―Apr―24 A strategy targeting monocyte-macrophage differentiation to avoid pulmonary complications in SARS-Cov2 infection J. Gómez-Rial
153 [GO] 2020―Apr―20 COVID-19 pathophysiology: A review Koichi Yuki, Miho Fujiogi, Sophia Koutsogiannaki
154 [GO] 2020―Apr―18 On the molecular determinants the SARS-CoV-2 attack Darja Kanduc, Yehuda Shoenfeld
155 [GO] 2020―Apr―10 COVID-19 - Considerations for the paediatric rheumatologist Christian M. Hedrich
156 [GO] 2020―Apr―08 COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster Yuanyuan Han, Mao Jiang, Da Xia, Lichao He, Xin Lv, Xiaohua Liao, Jie Meng
157 [GO] 2020―Apr―08 Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients Amr H. Sawalha, Ming Zhao, Patrick Coit, Qianjin Lu
158 [GO] 2020―Apr―07 Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic Amin Gasmi, Sadaf Noor, Torsak Tippairote, Maryam Dadar, Alain Menzel, Geir Bjørklund
159 [GO] 2020―Apr―01 Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19 Jie Ma, Peng Xia, Yangzhong Zhou, Zhengyin Liu, Xiang Zhou, Jinglan Wang, et al. (+6)
160 [GO] 2020―Mar―25 The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China Wen Zhang, Yan Zhao, Fengchun Zhang, Qian Wang, Taisheng Li, Zhengyin Liu, et al. (+6)

160 Results       Page 1


Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.006 sec